News & Updates

Treatment with pembrolizumab plus belzutifan results in a significant and clinically meaningful improvement in disease-free survival (DFS) compared with pembrolizumab monotherapy in patients with clear cell renal cell carcinoma (ccRCC) who are at greater risk of recurrence following nephrectomy, results from the phase III LITESPARK-022 study have shown.

COVID-19 vaccination appears to be moderately effective at preventing lingering symptoms following SARS-CoV-2 infection, and this effectiveness may increase with the number of doses administered, according to a meta-analysis.

Treatment with isoniazid and rifapentine (HP) either for 1 month daily (1HP) or 3 months weekly (3HP) results in high rates of treatment success among people with a positive latent tuberculosis infection test and without HIV infection, a study has shown. The 3HP regimen has slightly lower rates of adverse reactions, but neither exhibits superiority to the other.